

Sheet 1 of 1

PATENT FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Attorney Docket No.

00742/057002

Serial No.

09/829,040

Applicant

Yuan and Sanchez

Filing Date

April 9, 2001

Group

1645

IDS Filed

October 11, 2001

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. §1.98(b))

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
SW	WO 97/17445	May 15, 1997	PCT			
	WO 97/34567	Sept. 25, 1997	PCT			
	WO 97/35876	Oct. 2, 1997	PCT			
	WO 97/37652	Oct. 16, 1997	PCT			
	WO 97/40847	Nov. 6, 1997	PCT			
	WO 98/25920	Jun. 18, 1998	PCT			
	WO 98/38861	Sept. 11, 1998	PCT			
	WO 99/06838	Feb. 11, 1999	PCT			
	WO 99/10998	Mar. 4, 1999	PCT			
	WO 99/09825	Mar. 4, 1999	PCT			
	WO 99/33794	Jul. 8, 1999	PCT			
	WO 99/45947	Sept. 16, 1999	PCT			
	WO 99/51254	Oct. 14, 1999	PCT			
	WO 99/57566	Nov. 11, 1999	PCT			
	WO 99/58151	Nov. 18, 1999	PCT			
	WO 99/58982	Nov. 18, 1999	PCT			
SW	WO 99/59571	Nov. 25, 1999	PCT			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)



EXAMINER

S. L. W.

DATE CONSIDERED

6/6/03

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



RECEIVED
NOV 29 2001

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	00742/057002
		Serial No.	09/829,040
		Applicant	Yuan and Sanchez
		Filing Date	April 9, 2001
		Group	1645
		IDS Filed	October 11, 2001


U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
SL	WO 00/05260	Feb. 3, 2000	PCT	1	1	
	WO 00/04912	Feb. 3, 2000	PCT	1	1	
	WO 00/08470	Feb. 17, 2000	PCT	1	1	
	WO 00/10546	Mar. 2, 2000	PCT	1	1	
	WO 00/26675	May 11, 2000	PCT	1	1	
	WO 00/53217	Sept. 14, 2000	PCT	1	1	
	WO 00/68685	Nov. 16, 2000	PCT	1	1	
	WO 00/68251	Nov. 16, 2000	PCT	1	1	
	WO 01/12238	Feb. 22, 2001	PCT	1	1	
	WO 01/12654	Feb. 22, 2001	PCT	1	1	
	WO 01/23412	Apr. 5, 2001	PCT	1	1	
	WO 01/36588	May 25, 2001	PCT	1	1	
	WO 01/50134	Jul. 12, 2001	PCT	1	1	
	SL	WO 01/51522	Jul. 19, 2001	PCT	1	1

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	

EXAMINER S. L. Z	DATE CONSIDERED 6/6/03
------------------	------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



RECEIVED
OCT 16 2001
TECH CENTER 1600/2900
Sheet of 148

RECEIVED
NOV 29 2001

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))	Attorney Docket No.	00742/057002
	Serial No.	09/829,040
	Applicant	Yuan and Sanchez
	Filing Date	April 9, 2001
	Group	1645
IDS Filed	October 11, 2001	

U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)



FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
---	--

SW	Alafuzoff <i>et al.</i> , "Selegiline Treatment and the Extent of Degenerative Changes in Brain Tissue of Patients with Alzheimer's Disease," <i>Eur. J. Clin. Pharmacol.</i> 55:815-819 (2000).
	Askanas and Engel, "Inclusion-Body Myositis: Newest Concepts of Pathogenesis and Relation to Aging and Alzheimer Disease," <i>J. Neuropathol. Exp. Neurol.</i> 60:1-14 (2001).
	Bennett <i>et al.</i> , "Degradation of Amylin by Insulin-Degrading Enzyme," <i>J. Biol. Chem.</i> 275:36621-36625 (2000).
	Bruno <i>et al.</i> , "Selective Blockade of Metabotropic Glutamate Receptor Subtype 5 Is Neuroprotective," <i>Neuropharmacology</i> 39:2223-2230 (2000).
	Dalakas, "Molecular Immunology and Genetics of Inflammatory Muscle Diseases," <i>Arch. Neurol.</i> 55:1509-1512 (1998).
	Hauser <i>et al.</i> , "Time Course of Loss of Clinical Benefit Following Withdrawal of Levodopa/Carbidopa and Bromocriptine in Early Parkinson's Disease," <i>Mov. Disord.</i> 15:485-489 (2000).
	Heiser <i>et al.</i> , "Inhibition of Huntingtin Fibrillogenesis by Specific Antibodies and Small Molecules: Implication for Huntington's Disease Therapy," <i>Proc. Natl. Acad. Sci. USA</i> 97:6739-6744 (2000).
	Higaki <i>et al.</i> , "Inhibition of β -Amyloid Formation by Haloperidol: A Possible Mechanism for Reduced Frequency of Alzheimer's Disease Pathology in Schizophrenia," <i>J. Neurochem.</i> 68:333-336 (1997).
	Pasinelli <i>et al.</i> , "Caspase-1 and -3 Are Sequentially Activated in Motor Neuron Death in Cu,Zn Superoxide Dismutase-Mediated Familial Amyotrophic Lateral Sclerosis," <i>Proc. Natl. Acad. Sci. USA</i> 97:13901-13906 (2000).
	Pezzoli <i>et al.</i> , "Pergolide Mesylate in Parkinson's Disease Treatment," <i>J. Neural Transm. [Suppl.]</i> 45:203-212 (1995).
SW	Pulaski <i>et al.</i> , "The Combined Intervention of Therapy and Bromocriptine Mesylate to Improve Functional Performance after Brain Injury," <i>Am. J. Occup. Ther.</i> 48:263-270 (1994).

EXAMINER S. W. →	DATE CONSIDERED 6/6/03
---------------------	---------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



NOV 29 2001

RECEIVED

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.		0072057002	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))				Serial No.		09/829,042	
				Applicant		Yuan and Sanchez	
				Filing Date		April 9, 2001	
				Group		1645	
				IDS Filed		October 11, 2001	
U.S. PATENTS							
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
SW	Sánchez <i>et al.</i> , "Caspase-8 Is Required for Cell Death Induced by Expanded Polyglutamine Repeats," <i>Neuron</i> 22:623-633 (1999).						
SW	Subramanya <i>et al.</i> , "Assessment of Genotoxicity of Two Anti-Parkinsonian Drugs (Selegiline Hydrochloride and Bromocriptine Mesylate) <i>in vivo</i> in Mouse Bone Marrow Cells," <i>Toxicol. Lett.</i> 66:221-230 (1993).						
SW	Thomas, "Monoamine Oxidase-B Inhibitors in the Treatment of Alzheimer's Disease," <i>Neurobiol. Aging</i> 21:343-348 (2000).						
SW	Tyson <i>et al.</i> , "Prolactin-Secreting Macroadenomas in Adolescents. Response to Bromocriptine Therapy," <i>Am. J. Dis. Child.</i> 147:1057-1061 (1993).						
EXAMINER S. V. 7				DATE CONSIDERED 6/6/03			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Attorney Docket No. 00742/057002 Serial No. 09/829,040 Applicant Junying Yuan <i>et al.</i> Filing Date April 9, 2001 Group 1617 IDS Filed <i>April 9, 2003</i> Customer No. 21559				
U.S. PATENTS OR PATENT APPLICATION PUBLICATIONS						
Examiner's Initials	Patent Number	Issue/Publication Date	Patentee/Applicant	Class	Subclass	Filing Date (If Appropriate)
<i>SW</i>	6,177,259	01/23/01	Yuan et al.	435	23	08/05/99
<i>SW</i>	6,444,811	09/03/02	Han et al.	544	42	07/19/00
<i>SW</i>	2002/0009752	01/24/02	Burke et al.	435	7.1	02/09/01
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
<i>SW</i>	Li et al., "Functional Role of Caspase-1 and Caspase-3 in an ALS Transgenic Mouse Model," <i>Science</i> 288:335-339, (2000).					
EXAMINER <i>S. U. O</i>			DATE CONSIDERED <i>6/6/03</i>			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						